Savara Inc Cash Acquired from Acquisition
Savara Inc (SVRA) reported Cash Acquired from Acquisition of $3.44 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-13.
Discontinued › Cash Flow
us-gaap:CashAcquiredFromAcquisition · last filed 2019-03-13
- Savara Inc cash acquired from acquisition for the quarter ending 2017-12-31 was $0.00.
- Savara Inc cash acquired from acquisition for the quarter ending 2017-09-30 was $0.00.
- Savara Inc cash acquired from acquisition for the quarter ending 2014-12-31 was $0.00.
- Savara Inc cash acquired from acquisition for the quarter ending 2014-09-30 was $0.00.
- Savara Inc cash acquired from acquisition for fiscal 2017 was $3.44M.
- Savara Inc cash acquired from acquisition for fiscal 2014 was $3.53M.
| Period end | Cash Acquired from Acquisition 3 month | Cash Acquired from Acquisition 3 month as first filed | Cash Acquired from Acquisition 6 month | Cash Acquired from Acquisition 6 month as first filed | Cash Acquired from Acquisition 9 month | Cash Acquired from Acquisition 9 month as first filed | Cash Acquired from Acquisition 12 month | Cash Acquired from Acquisition 181 month | Cash Acquired from Acquisition 184 month | Cash Acquired from Acquisition 193 month | Cash Acquired from Acquisition 196 month | Cash Acquired from Acquisition 199 month | Cash Acquired from Acquisition 202 month | Cash Acquired from Acquisition 205 month | Cash Acquired from Acquisition 208 month | Cash Acquired from Acquisition 211 month | Cash Acquired from Acquisition 214 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $0.00 derived: sum of 2 quarters · filed 2019-03-13 | $3.44M 10-K · filed 2019-03-13 | ||||||||||||||
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $3.44M 10-Q · filed 2018-11-07 | |||||||||||||||
| 2017-06-30 | $3.44M 10-Q · filed 2018-08-09 | ||||||||||||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06 | $0.00 derived: sum of 2 quarters · filed 2017-03-06 | $0.00 derived: sum of 3 quarters · filed 2017-03-06 | $3.53M 10-K · filed 2017-03-06 | |||||||||||||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $0.00 derived: sum of 2 quarters · filed 2015-11-12 | $3.53M 10-Q · filed 2015-11-12 | $3.53M 10-Q · filed 2014-10-31 | |||||||||||||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | $3.53M 10-Q · filed 2015-08-12 | $3.53M 10-Q · filed 2014-08-11 | ||||||||||||||
| 2014-03-31 | $3.53M 10-Q · filed 2015-05-11 | $3.53M 10-Q · filed 2014-05-05 | $3.57M 10-Q · filed 2014-05-05 | ||||||||||||||
| 2013-12-31 | $32.40K 10-K · filed 2014-03-26 | ||||||||||||||||
| 2013-09-30 | $32.40K 10-Q · filed 2013-11-04 | ||||||||||||||||
| 2013-06-30 | $32.40K 10-Q · filed 2013-08-05 | ||||||||||||||||
| 2013-03-31 | $32.40K 10-Q · filed 2013-05-15 | ||||||||||||||||
| 2012-12-31 | $32.40K 10-K · filed 2013-03-19 | ||||||||||||||||
| 2012-09-30 | $32.40K 10-Q · filed 2012-11-05 | ||||||||||||||||
| 2012-06-30 | $32.40K 10-Q · filed 2012-08-06 | ||||||||||||||||
| 2011-09-30 | $32.40K 10-Q · filed 2011-11-08 | ||||||||||||||||
| 2011-06-30 | $32.40K 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |